Company intelligence / Profile preview
Stratus Therapeutics
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Stratus Therapeutics’ most advanced product, ST-101, is an off-the-shelf hematopoietic stem cell therapy composed of Prime HSCs™ and Prime HPCs™ engineered for full hematopoietic and immune system renewal, aiming to eliminate the need for matched donors and reduce risk of graft-versus-host disease. As of mid-2025, the program is advancing towards early clinical trials but has not yet reported clinical outcomes[1][2][3][4].
- Therapeutic areas
- OncologyHematology
- Modalities
- Cell therapyInduced pluripotent stem cell derived therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Stratus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stratus Therapeutics.